Overall, the high sensitivity and precision of ddPCR make it a robust platform for clinical BRCA1/2 CNV testing, enabling improved biomarker detection and supporting personalized treatment strategies in advanced prostate cancer. The gene discussed is BRCA1; the disease is prostate carcinoma.